Entry of hepatitis delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange.
Hepatitis delta virus (HDV) particles are coated with the envelope proteins (large, middle, and small) of the hepatitis B virus (HBV). The large protein bears an infectivity determinant in its pre-S1 domain, whereas a second determinant has been proposed to map to the cysteine-rich antigenic loop (AGL) within the S domain of all three envelope proteins (G. Abou Jaoudé and C. Sureau, J. Virol. 79:10460-10466, 2006). In this study, the AGL cysteines were substituted by serine or alanine, and the mutants were evaluated for their function at viral entry using HDV particles and susceptible HepaRG cells. Mutations of cysteines 121 to 149 were tolerant of the production of HDV virions. The mutations altered the structure and antigenicity of the conserved "a" determinant of the AGL, as measured by conformation-sensitive antibodies, and they created a block to infectivity. Substitution of Cys-90 or Cys-221, located outside of the AGL, had no impact on the "a" determinant or viral entry. Furthermore, infectivity was maintained when the AGL CxxC motif at position 121 to 124 was modified by single-amino-acid deletion or insertion, suggesting that cysteines 121 and 124 are not catalyzers of thiol/disulfide exchange. However, membrane-impermeable inhibitors of thiol/disulfide isomerazation demonstrated a dose-dependent inhibition of infection in an in vitro assay when applied to the virus prior to inoculation or during the virus-cell interaction period. Overall, the results demonstrate the essential role of the AGL cysteines at viral entry, and they establish a correlation between the cysteine disulfide network, the conformation of the "a" determinant, and infectivity.
Abou-Jaoudé
Georges
G
Laboratoire de Virologie Moléculaire, Institut National de la Transfusion Sanguine, 6 Rue Alexandre-Cabanel, 75739 Paris, France.
Sureau
Camille
C
D000477:Alkylating Agents / Q000494:pharmacology; D000914:Antibodies, Viral / Q000378:metabolism; D000956:Antigens, Viral / Q000737:chemistry / Q000276:immunology / Q000502:physiology; D000998:Antiviral Agents / Q000494:pharmacology; D002460:Cell Line; D003545:Cysteine / Q000235:genetics*; D003698:Hepatitis Delta Virus / Q000737:chemistry / Q000276:immunology / Q000502:physiology*; D006801:Humans; D016297:Mutagenesis, Site-Directed; D011487:Protein Conformation; D017434:Protein Structure, Tertiary / Q000235:genetics; D011995:Recombination, Genetic; D019163:Reducing Agents / Q000494:pharmacology; D017384:Sequence Deletion; D014759:Viral Envelope Proteins / Q000737:chemistry / Q000276:immunology / Q000502:physiology*; D053586:Virus Internalization / Q000187:drug effects*
D000477:Alkylating Agents; D000914:Antibodies, Viral; D000956:Antigens, Viral; D000998:Antiviral Agents; D019163:Reducing Agents; C118669:S envelope protein, hepatitis B virus; D014759:Viral Envelope Proteins; D003545:Cysteine